vs
agilon health, inc.（AGL）与Evercore Inc.（EVR）财务数据对比。点击上方公司名可切换其他公司
agilon health, inc.的季度营收约是Evercore Inc.的1.2倍（$1.6B vs $1.3B），Evercore Inc.净利率更高（15.7% vs -12.0%，领先27.8%），Evercore Inc.同比增速更快（32.4% vs 3.1%），Evercore Inc.自由现金流更多（$798.6M vs $-23.5M），过去两年Evercore Inc.的营收复合增速更高（48.9% vs -1.1%）
agilon health是一家美国医疗保健企业，主要与基层医疗服务提供者合作，为联邦医疗保险覆盖的老年群体提供价值导向型医疗解决方案，为医生提供行政支持、临床工具及风险管理框架，在提升诊疗效果的同时降低医疗成本，业务覆盖美国20余个州。
Evercore Inc.（前称Evercore Partners）是1995年由罗杰·奥尔特曼、大卫·奥芬森德、奥斯汀·博伊特纳联合创立的全球独立投资银行咨询机构。成立至今，公司已为总规模超4.7万亿美元的并购、重组交易提供专业咨询服务，在全球投行业务领域拥有较高声誉。
AGL vs EVR — 直观对比
营收规模更大
AGL
是对方的1.2倍
$1.3B
营收增速更快
EVR
高出29.3%
3.1%
净利率更高
EVR
高出27.8%
-12.0%
自由现金流更多
EVR
多$822.1M
$-23.5M
两年增速更快
EVR
近两年复合增速
-1.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $1.3B |
| 净利润 | $-188.9M | $204.0M |
| 毛利率 | — | — |
| 营业利润率 | -12.3% | 24.2% |
| 净利率 | -12.0% | 15.7% |
| 营收同比 | 3.1% | 32.4% |
| 净利润同比 | -78.5% | 45.2% |
| 每股收益（稀释后） | — | $4.80 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGLEVR
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | $1.4B | $838.0M | ||
| Q1 25 | $1.5B | $699.0M | ||
| Q4 24 | $1.5B | $979.5M | ||
| Q3 24 | $1.5B | $738.4M | ||
| Q2 24 | $1.5B | $693.4M | ||
| Q1 24 | $1.6B | $585.0M |
净利润AGLEVR
| Q4 25 | $-188.9M | $204.0M | ||
| Q3 25 | $-110.2M | $144.6M | ||
| Q2 25 | $-104.4M | $97.2M | ||
| Q1 25 | $12.1M | $146.2M | ||
| Q4 24 | $-105.8M | $140.4M | ||
| Q3 24 | $-117.6M | $78.4M | ||
| Q2 24 | $-30.7M | $73.8M | ||
| Q1 24 | $-6.1M | $85.7M |
营业利润率AGLEVR
| Q4 25 | -12.3% | 24.2% | ||
| Q3 25 | -9.1% | 20.8% | ||
| Q2 25 | -8.3% | 18.0% | ||
| Q1 25 | -1.4% | 16.0% | ||
| Q4 24 | -7.1% | 21.8% | ||
| Q3 24 | -9.2% | 16.7% | ||
| Q2 24 | -2.9% | 15.9% | ||
| Q1 24 | -0.4% | 14.8% |
净利率AGLEVR
| Q4 25 | -12.0% | 15.7% | ||
| Q3 25 | -7.7% | 13.8% | ||
| Q2 25 | -7.5% | 11.6% | ||
| Q1 25 | 0.8% | 20.9% | ||
| Q4 24 | -6.9% | 14.3% | ||
| Q3 24 | -8.1% | 10.6% | ||
| Q2 24 | -2.1% | 10.6% | ||
| Q1 24 | -0.4% | 14.6% |
每股收益（稀释后）AGLEVR
| Q4 25 | — | $4.80 | ||
| Q3 25 | — | $3.41 | ||
| Q2 25 | — | $2.36 | ||
| Q1 25 | — | $3.48 | ||
| Q4 24 | — | $3.32 | ||
| Q3 24 | — | $1.86 | ||
| Q2 24 | — | $1.81 | ||
| Q1 24 | — | $2.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $173.7M | $3.0B |
| 总债务越低越好 | $35.0M | — |
| 股东权益账面价值 | $126.7M | $2.0B |
| 总资产 | $1.3B | $5.4B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资AGLEVR
| Q4 25 | $173.7M | $3.0B | ||
| Q3 25 | $171.7M | $2.4B | ||
| Q2 25 | $171.4M | $1.7B | ||
| Q1 25 | $136.9M | $1.4B | ||
| Q4 24 | $188.2M | $2.4B | ||
| Q3 24 | $148.2M | $1.8B | ||
| Q2 24 | $109.5M | $1.7B | ||
| Q1 24 | $111.7M | $1.4B |
总债务AGLEVR
| Q4 25 | $35.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AGLEVR
| Q4 25 | $126.7M | $2.0B | ||
| Q3 25 | $306.1M | $1.8B | ||
| Q2 25 | $408.9M | $1.7B | ||
| Q1 25 | $500.3M | $1.5B | ||
| Q4 24 | $471.0M | $1.7B | ||
| Q3 24 | $574.9M | $1.6B | ||
| Q2 24 | $676.6M | $1.5B | ||
| Q1 24 | $689.3M | $1.4B |
总资产AGLEVR
| Q4 25 | $1.3B | $5.4B | ||
| Q3 25 | $1.6B | $4.4B | ||
| Q2 25 | $1.7B | $3.7B | ||
| Q1 25 | $1.9B | $3.3B | ||
| Q4 24 | $1.7B | $4.2B | ||
| Q3 24 | $2.1B | $3.6B | ||
| Q2 24 | $2.2B | $3.3B | ||
| Q1 24 | $2.3B | $3.0B |
负债/权益比AGLEVR
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.5M | $807.5M |
| 自由现金流经营现金流 - 资本支出 | $-23.5M | $798.6M |
| 自由现金流率自由现金流/营收 | -1.5% | 61.6% |
| 资本支出强度资本支出/营收 | 0.2% | 0.7% |
| 现金转化率经营现金流/净利润 | — | 3.96× |
| 过去12个月自由现金流最近4个季度 | $-119.0M | $1.2B |
8季度趋势，按日历期对齐
经营现金流AGLEVR
| Q4 25 | $-20.5M | $807.5M | ||
| Q3 25 | $-18.2M | $560.9M | ||
| Q2 25 | $-35.1M | $437.7M | ||
| Q1 25 | $-32.0M | $-549.7M | ||
| Q4 24 | $16.4M | $686.4M | ||
| Q3 24 | $-7.7M | $234.5M | ||
| Q2 24 | $-18.7M | $348.5M | ||
| Q1 24 | $-47.8M | $-281.2M |
自由现金流AGLEVR
| Q4 25 | $-23.5M | $798.6M | ||
| Q3 25 | $-21.3M | $541.5M | ||
| Q2 25 | $-38.3M | $411.7M | ||
| Q1 25 | $-35.8M | $-569.3M | ||
| Q4 24 | $13.2M | $673.1M | ||
| Q3 24 | $-11.2M | $226.6M | ||
| Q2 24 | $-22.0M | $340.7M | ||
| Q1 24 | $-50.9M | $-282.3M |
自由现金流率AGLEVR
| Q4 25 | -1.5% | 61.6% | ||
| Q3 25 | -1.5% | 51.8% | ||
| Q2 25 | -2.7% | 49.1% | ||
| Q1 25 | -2.3% | -81.4% | ||
| Q4 24 | 0.9% | 68.7% | ||
| Q3 24 | -0.8% | 30.7% | ||
| Q2 24 | -1.5% | 49.1% | ||
| Q1 24 | -3.2% | -48.3% |
资本支出强度AGLEVR
| Q4 25 | 0.2% | 0.7% | ||
| Q3 25 | 0.2% | 1.9% | ||
| Q2 25 | 0.2% | 3.1% | ||
| Q1 25 | 0.3% | 2.8% | ||
| Q4 24 | 0.2% | 1.4% | ||
| Q3 24 | 0.2% | 1.1% | ||
| Q2 24 | 0.2% | 1.1% | ||
| Q1 24 | 0.2% | 0.2% |
现金转化率AGLEVR
| Q4 25 | — | 3.96× | ||
| Q3 25 | — | 3.88× | ||
| Q2 25 | — | 4.50× | ||
| Q1 25 | -2.64× | -3.76× | ||
| Q4 24 | — | 4.89× | ||
| Q3 24 | — | 2.99× | ||
| Q2 24 | — | 4.72× | ||
| Q1 24 | — | -3.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGL
| Medical Services | $1.6B | 100% |
| Other Operating | $2.5M | 0% |
EVR
| Advisory Fees | $1.1B | 87% |
| Commissions And Related Revenue | $66.5M | 5% |
| Underwriting Fees | $49.5M | 4% |
| Other | $29.6M | 2% |
| Investment Management | $23.2M | 2% |
